Consider 505(b)(2) Pathway [Design Issues]

posted by bebac_fan – US, 2018-05-05 19:08 (2153 d 18:42 ago) – Posting: # 18756
Views: 2,794

I think this would need to go through a NDA/505(b)(2) pathway rather than an ANDA.

In this case, comparative efficacy, rather than BE, will be considered pivotal.

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,639 registered users;
79 visitors (0 registered, 79 guests [including 6 identified bots]).
Forum time: 12:51 CET (Europe/Vienna)

Nothing shows a lack of mathematical education more
than an overly precise calculation.    Carl Friedrich Gauß

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5